KBC Group
CRL icon

KBC Group’s Charles River Laboratories CRL Stock Holding History

KBC Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
1,588
+222
+16% +$41.2K ﹤0.01% 892
2025
Q4 		$272K Hold
1,366
– – ﹤0.01% 812
2025
Q3 		$214K Hold
1,366
– – ﹤0.01% 877
2025
Q2 		$207K Sell
1,366
-74,940
-98% -$9.99M ﹤0.01% 850
2025
Q1 		$11.5M Sell
76,306
-9,056
-11% -$1.52M 0.04% 334
2024
Q4 		$15.8M Buy
85,362
+796
+0.9% +$153K 0.04% 309
2024
Q3 		$16.7M Sell
84,566
-50,319
-37% -$10.5M 0.05% 292
2024
Q2 		$27.9M Sell
134,885
-741
-0.5% -$168K 0.08% 200
2024
Q1 		$36.7M Sell
135,626
-80,013
-37% -$19.1M 0.12% 171
2023
Q4 		$51M Sell
215,639
-2,875
-1% -$565K 0.18% 124
2023
Q3 		$42.8M Buy
218,514
+213,341
+4,124% +$43.8M 0.17% 127
2023
Q2 		$1.09M Buy
5,173
+80
+2% +$15.9K ﹤0.01% 690
2023
Q1 		$1.03M Sell
5,093
-1,738
-25% -$394K ﹤0.01% 716
2022
Q4 		$1.49M Buy
6,831
+3,653
+115% +$798K 0.01% 648
2022
Q3 		$625K Sell
3,178
-19
-0.6% -$4.1K ﹤0.01% 728
2022
Q2 		$684K Buy
3,197
+225
+8% +$55K ﹤0.01% 716
2022
Q1 		$844K Sell
2,972
-65,014
-96% -$20M ﹤0.01% 723
2021
Q4 		$25.6M Sell
67,986
-2,650
-4% -$1.03M 0.08% 232
2021
Q3 		$29.1M Buy
70,636
+54,410
+335% +$22.6M 0.11% 207
2021
Q2 		$6M Buy
+16,226
New +$5.42M 0.01% 584
2015
Q3 		– Sell
-2,047
Closed -$144K – 1347
2015
Q2 		$144K Sell
2,047
-248
-11% -$18.4K ﹤0.01% 1182
2015
Q1 		$182K Sell
2,295
-877
-28% -$64.7K ﹤0.01% 1143
2014
Q4 		$202K Sell
3,172
-62,561
-95% -$3.92M ﹤0.01% 1190
2014
Q3 		$3.93M Sell
65,733
-5,764
-8% -$330K 0.14% 209
2014
Q2 		$3.83M Buy
+71,497
New +$3.92M 0.04% 444

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KBC Group's CRL Position: Q1 2026 in Review

KBC Group increased its Charles River Laboratories (CRL) stake by 16% in Q1 2026, buying an estimated $41.2K and bringing the position to 1,588 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

KBC Group first reported a position in CRL in Q2 2014 and has held it in 25 quarters since. The position peaked at $51M in Q4 2023. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • KBC Group held 1,588 shares of Charles River Laboratories worth $274K as of Q1 2026.
  • KBC Group bought 222 Charles River Laboratories shares in Q1 2026, an estimated $41.2K.
  • Charles River Laboratories made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #892 holding.
  • KBC Group first reported a position in Charles River Laboratories in Q2 2014 and has held it in 25 quarters since.
  • KBC Group's Charles River Laboratories position peaked at $51M in Q4 2023.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.